Vertex Pharmaceuticals Incorporated

NasdaqGS:VRTX Rapport sur les actions

Capitalisation boursière : US$115.4b

Vertex Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Le PDG Vertex Pharmaceuticals est Reshma Kewalramani, nommé en Apr2020, a un mandat de 4.58 ans. La rémunération annuelle totale est $ 20.59M, composée du salaire de 7.3% et des bonus 92.7%, y compris les actions et options de la société. détient directement 0.029% des actions de la société, d'une valeur de $ 33.94M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.1 ans et 4.8 ans.

Informations clés

Reshma Kewalramani

Directeur général

US$20.6m

Rémunération totale

Pourcentage du salaire du PDG7.3%
Durée du mandat du directeur général4.6yrs
Propriété du PDG0.03%
Durée moyenne d'occupation des postes de direction5.1yrs
Durée moyenne du mandat des membres du conseil d'administration4.8yrs

Mises à jour récentes de la gestion

Recent updates

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Nov 05

Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride

Oct 18

Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)

Oct 10

Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug

Sep 15

Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced

Sep 05

Vertex Stock: Came For CF Drugs, Staying For Gene Therapy

Aug 02

Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Jul 11
Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Jul 09

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jun 20
If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales

Jun 17

Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time

Jun 04

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

May 09
Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 08
Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Apr 11

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Apr 05
Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15
Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22
We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07
Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25
Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03
We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Analyse de la rémunération des PDG

Comment la rémunération de Reshma Kewalramani a-t-elle évolué par rapport aux bénéfices de Vertex Pharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$480m

Jun 30 2024n/an/a

-US$490m

Mar 31 2024n/an/a

US$4b

Dec 31 2023US$21mUS$2m

US$4b

Sep 30 2023n/an/a

US$3b

Jun 30 2023n/an/a

US$3b

Mar 31 2023n/an/a

US$3b

Dec 31 2022US$16mUS$1m

US$3b

Sep 30 2022n/an/a

US$3b

Jun 30 2022n/an/a

US$3b

Mar 31 2022n/an/a

US$2b

Dec 31 2021US$15mUS$1m

US$2b

Sep 30 2021n/an/a

US$2b

Jun 30 2021n/an/a

US$2b

Mar 31 2021n/an/a

US$3b

Dec 31 2020US$9mUS$1m

US$3b

Sep 30 2020n/an/a

US$3b

Jun 30 2020n/an/a

US$2b

Mar 31 2020n/an/a

US$2b

Dec 31 2019US$7mUS$702k

US$1b

Rémunération vs marché: La rémunération totale de Reshma ($USD 20.59M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 12.73M ).

Rémunération et revenus: La rémunération de Reshma a augmenté alors que l'entreprise n'est pas rentable.


PDG

Reshma Kewalramani (51 yo)

4.6yrs

Titularisation

US$20,594,441

Compensation

Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Jeffrey Leiden
Executive Chairman15.3yrsUS$6.60m0.0040%
$ 4.7m
Reshma Kewalramani
CEO, President & Director4.6yrsUS$20.59m0.029%
$ 33.9m
Charles Wagner
Executive VP & CFO5.6yrsUS$7.37m0.017%
$ 19.8m
Stuart Arbuckle
Executive VP & COO3.3yrsUS$9.00m0.019%
$ 22.3m
David Altshuler
Executive VP & Chief Scientific Officer9.8yrsUS$6.54m0.010%
$ 11.6m
Kristen Ambrose
Senior VP & Chief Accounting Officer3.5yrspas de données0.0029%
$ 3.4m
Mike Tirozzi
SVP and Chief Information & Data Officer5.8yrspas de donnéespas de données
Susie Lisa
Senior Vice President of Investor Relations2.2yrspas de donnéespas de données
Jonathan Biller
Executive VP & Chief Legal Officer2.2yrspas de données0.0065%
$ 7.5m
Nina Devlin
Senior VP & Chief Communications Officer5.8yrspas de donnéespas de données
Stephanie Franklin
Senior VP & Chief Human Resources Officer7.3yrspas de donnéespas de données
Amit Sachdev
Executive VP & Chief Patient and External Affairs Officer17.3yrsUS$6.20m0.023%
$ 26.1m

5.1yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de VRTX est chevronnée et expérimentée (5.1 années d'ancienneté moyenne).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Jeffrey Leiden
Executive Chairman15.3yrsUS$6.60m0.0040%
$ 4.7m
Reshma Kewalramani
CEO, President & Director4.8yrsUS$20.59m0.029%
$ 33.9m
Bruce Sachs
Lead Independent Director26.8yrsUS$600.04k0.016%
$ 17.9m
Alan Garber
Independent Director7.4yrsUS$537.63k0.0023%
$ 2.6m
Lloyd Carney
Independent Director5.8yrsUS$559.79k0.0021%
$ 2.4m
Sangeeta Bhatia
Independent Director9.4yrsUS$550.31k0.0013%
$ 1.5m
Michel Lagarde
Independent Director1.1yrsUS$449.08kpas de données
Diana McKenzie
Independent Director4.4yrsUS$553.11k0.00064%
$ 738.4k
Suketu Upadhyay
Independent Director2.5yrsUS$544.66k0.00060%
$ 692.3k
Nancy Thornberry
Independent Directorless than a yearUS$407.65kpas de données
Jennifer Schneider
Independent Directorless than a yearpas de donnéespas de données

4.8yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de VRTX sont considérés comme expérimentés (ancienneté moyenne 4.8 ans).